"We are beginning with three products and have plans to launch at least 25 brands by next year," managing director Bodo Rasler said on Wednesday.
"We want allopathic chemists to stock our products," he said. At present, chemists are allowed to sale only certain categories of homoeopathic medicines listed in the schedule K of the Drugs and Cosmetics Rule. Most homoeopathic drugs are sold through dealers licensed to sell specific categories of drugs in India.
According to Rasler, one third of the homoeopathic medicines in India are sold as over the counter products and the rest as prescription drugs. While more than 60% people use homoeopathy mainly for lesser side effects, only 3%-4% is actual user in India.
Schwabe India reported a turnover of Rs 30 crore last year and has targeted Rs 40 crore by 2008. It also exports to neighbouring countries like Bangladesh and Sri Lanka.
The company plans to invest Rs 30 crore for a new warehouse and dispatch centre.
Dr Wilmer Schwabe Group, headquartered in Germany, has its presence in 68 countries. It has an annual turnover of Euro 500 million, and invests around Euro 50 million for research and development.
"The group is conducting researches in the fields like immune system, cardiovascular and infectious diseases," Rasler said. The company's research also focuses on the therapeutic fields of dementia, depression and gastrointestinal disorders.
Bharat Bharadwaj, marketing manager of Schwabe India, said the Rs 950-crore market in India has been growing at 15%-20% per annum for the last three years.